BrightGene Bio-Medical Technology Co., Ltd. Provided earnings guidance for the year 2019. The company predicts that the net profit belonging to owners of the parent company in 2019 will be between RMB 102.48 million and RMB 117.12 million with an increase of between RMB 29.28 million and RMB 43.92 million and an increase of between 40% and 60% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations). The net profit belonging to owners of the parent company after excluding extraordinary profit and loss in 2019 will be between RMB 100.68 million and RMB 115.06 million with an increase of between RMB 28.76 million and RMB 43.14 million and an increase of between 40% and 60% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations).